Flamic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flamic

Property Description
Active ingredient Diclofenac (usually as Diclofenac Sodium)
Form Tablets, injection solution, suppositories, topical gel
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief from pain, inflammation, and fever
Origin Synthetic compound (Phenylacetic acid derivative)

Flamic is a prescription-only medicinal product containing the active substance Diclofenac, which is clinically recognized as a potent Nonsteroidal Anti-inflammatory Drug (NSAID). Its fundamental purpose is to mitigate symptoms arising from the body's inflammatory responses, providing comprehensive relief from associated pain, swelling, and fever.


What Type of Medicine is Flamic?

Flamic is defined by its core ingredient, Diclofenac, a synthetic compound that functions primarily as an inhibitor of the cyclooxygenase (COX) enzyme system. This mechanism positions it squarely within the NSAID class of drugs, a classification widely recognized for managing pain and inflammation. Diclofenac is a carboxylic acid derivative with established analgesic and anti-inflammatory activity. This type of medicine is used to reduce both inflammation and pain across various systemic conditions. The potency of Diclofenac differentiates it within the broader NSAID group, making it a standard choice for conditions where robust control of inflammation is required.


Composition and Physical Forms of Flamic

The therapeutic efficacy of Flamic is delivered through its single-ingredient product composition, where Diclofenac Sodium is the sole active agent. To accommodate varied therapeutic needs, Diclofenac is manufactured across numerous dosage forms for systemic and localized action. These preparations include film-coated tablets for oral intake, solution for injection for parenteral administration, suppositories for rectal use, and topical gel for dermal application. Diclofenac is available in multiple routes of administration, and the choice of form is essential for achieving either local or systemic effects. This versatility allows for the selection of the most appropriate delivery method, depending on whether the condition is localized or widespread.


General Purpose and Core Benefits

The general purpose of Flamic is established by its mechanism of action, which directly impacts the body's physiological response to injury or irritation. By decreasing the production of inflammatory mediators, the drug provides a robust benefit: an analgesic effect that reduces pain perception, a pronounced anti-inflammatory effect that mitigates swelling, and an antipyretic effect that helps normalize an elevated body temperature. For example, its usage is well-established in controlling the inflammation and associated pain typical of musculoskeletal discomfort. This action establishes Flamic as a reliable agent for the systemic management of discomfort and inflammation.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information
  2. Diclofenac's Anti-inflammatory Activity and Mechanism of Action - PMC (NIH)

What side effects are possible with Flamic?

The safety profile of Flamic (Diclofenac) is officially documented by government regulatory bodies, classifying adverse reactions by frequency and the organ systems affected.

Classification of Common Adverse Reactions

Adverse reactions classified as common in official labeling primarily involve the Gastrointestinal System, and typically include abdominal pain, nausea, vomiting, diarrhea, indigestion (dyspepsia), and flatulence. Effects on the Nervous System, such as headache and dizziness, are also frequently reported.

Serious System-Organ Adverse Events

Regulatory documents highlight the potential for serious, sometimes fatal, events across critical systems:

  • Serious Gastrointestinal (GI) Events: The drug carries a documented risk of bleeding, ulceration, and perforation of the stomach or intestines. These can occur at any time during treatment, often without prior warning symptoms.
  • Cardiovascular Thrombotic Events: An increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (heart attack) and stroke, is associated with NSAID use. This risk may increase with the duration of use.
  • Hepatobiliary and Renal Events: Severe Hepatotoxicity (liver injury) and Renal Toxicity (kidney damage) are officially noted as potential serious adverse reactions.

Time-Related and Population-Specific Safety Considerations

The official safety profile includes specific constraints based on exposure and patient status:

  • Duration of Use: The risk of both serious GI and cardiovascular events is officially noted to increase with the duration of use of the medicine.
  • Special Populations: Older adults are documented as being at a greater risk for serious GI adverse events. The medicine is contraindicated in patients with established severe cardiovascular disease, such as Congestive Heart Failure (NYHA class II-IV).
  • Pregnancy: Use is contraindicated during the last trimester of pregnancy due to documented fetal risks.

Overdose and Emergency Response

The official regulatory profile for Flamic (Diclofenac) overdose strictly defines both the expected manifestations and the required emergency response actions.

Documented Manifestations and Severe Outcomes

An acute overdose is associated with documented clinical manifestations across multiple physiological systems. These initial signs may include gastrointestinal distress such as nausea, vomiting, and abdominal pain. Central nervous system effects are also officially recognized, presenting as drowsiness, confusion, and agitation. However, the primary regulatory concern relates to severe, life-threatening outcomes, which include acute renal failure, significant gastrointestinal bleeding, ulceration, and perforation. Neurological emergencies such as seizures and coma are also documented complications of severe toxicity.

Mandated Emergency Action and Management

Due to the high potential for severe organ toxicity, regulatory guidance mandates that individuals seek immediate medical help right away and contact a Poison Control Center following suspected overdose. The official labeling confirms that no specific antidote is known for Diclofenac toxicity. Management is therefore directed toward symptomatic and supportive care. Procedures such as the administration of Activated Charcoal may be considered in a supervised medical setting. Hospital monitoring, including vital signs and specific diagnostic tests, may be required. Furthermore, official documentation notes that patients with asthma or pre-existing conditions may face increased risk of severe effects.

Therapeutic Uses of Flamic

What Flamic Treats: Main Uses and Benefits

Flamic is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed. Its use is applied across therapeutic domains where additional support is required to ease discomfort. This medication is commonly used to help with mild to moderate acute pain.

This support is considered relevant for easing primary dysmenorrhea (menstrual pain and cramps), which is a clinical scenario that often involves symptoms related to physical discomfort. It is also applied in addressing symptom clusters that may become intense or disruptive, such as headaches, dental pain, and muscular aches. This supportive relief assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

The primary role of Flamic is to provide supportive relief when symptoms interfere with routine activities.

Quick Fact: Supports Management of Acute Symptom Clusters

Regulatory References

  1. NIH MedlinePlus Drug Information on Mefenamic Acid

Eligibility and Restrictions for Use

Flamic is a prescription-only medicine (Diclofenac) whose use is defined by strict regulatory population eligibility criteria based on health status and age.

Populations for Whom Use is Contraindicated

Official labeling mandates that Flamic must not be used by patients who have an absolute non-eligibility due to:

  • Prior Allergy: History of asthma, urticaria, or severe allergic-type reactions after taking aspirin or any other NSAID.
  • Cardiovascular Disease: Established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Gastrointestinal History: Active or history of recurrent peptic ulcer, gastrointestinal haemorrhage, or perforation.
  • Late Pregnancy: Use in the third trimester of pregnancy (starting at 30 weeks gestation) due to risk of fetal harm.

Restricted and Conditional Use

Use is often restricted or requires special consideration in several patient groups:

  • Organ Function: Patients with severe renal or hepatic failure are generally ineligible; those with mild-to-moderate impairment require caution and monitoring.
  • Cardiovascular Risk: Use is generally not recommended for patients with risk factors for heart events, such as uncontrolled hypertension or high cholesterol.
  • Age Limits: The medicine is generally approved for adults. For the pediatric population, specific formulations may be approved for children 6 years of age and older. Older adults require the lowest effective dose for the shortest duration due to increased risk of serious gastrointestinal events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents categorize Flamic's interactions primarily by the resulting clinical effect, necessitating careful consideration when co-administered with numerous medicinal products.

Regulatory Contraindications and High-Risk Combinations

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin (used as an analgesic), is officially contraindicated due to a significantly increased risk of serious gastrointestinal (GI) adverse events. Flamic is also officially contraindicated in the peri-operative setting of coronary artery bypass graft (CABG) surgery.

Pharmacodynamic and Exposure-Altering Interactions

Official labeling documents a risk of pharmacodynamic reinforcement with several drug classes:

  • Increased Bleeding Risk: Combination with Anticoagulants, Antiplatelet Agents, SSRIs, and Corticosteroids is associated with an officially documented increased risk of serious bleeding events.
  • Antihypertensive Reduction: Flamic may officially diminish the antihypertensive or natriuretic effect of Diuretics, ACE Inhibitors, and ARBs (Angiotensin Receptor Blockers).

Additionally, Flamic is officially documented to increase the serum concentration of co-administered Lithium, Methotrexate, and Digoxin by reducing their renal clearance.

Specific Interaction Constraints

  • Metabolic: The potent CYP inhibitor Voriconazole significantly increases Flamic's plasma exposure, an officially documented pharmacokinetic interaction.
  • Alcohol and Food: Use with Alcohol is discouraged due to an increased risk of serious GI problems. Specific oral solution forms must be taken on an empty stomach, as food officially reduces effectiveness.
  • Population Note: A greater risk of renal function deterioration is officially documented for elderly, volume-depleted, or renal-impaired patients when co-administered with ACE Inhibitors, ARBs, or Diuretics.

Mechanism of Action

Molecular Mechanism: Inhibition of Prostaglandin Synthesis

Flamic's mechanism is anchored by its non-selective inhibition of the Cyclooxygenase (COX) enzymes, specifically both the constitutive COX-1 and inducible COX-2 isoforms. This targeted enzyme blockade prevents the conversion of Arachidonic Acid into key signaling molecules, notably the pro-inflammatory prostaglandins ( PGE2 and PGI2). This early molecular suppression reduces the formation of eicosanoids that mediate physiological hyper-responsiveness.


Modulation of Nociceptive and Thermoregulatory Pathways

The downstream consequence of prostaglandin reduction is a modulation of central and peripheral signaling. Peripherally, the lowered PGE2 concentration reduces the sensitization of nociceptors (pain receptors), thereby decreasing the input of afferent signals transmitted to the central nervous system. Centrally, the inhibition of PGE2 within the hypothalamus prevents the PGE2-induced elevation of the body’s temperature set point. These coordinated actions result in the modulation of PGE2-dependent physiological feedback loops across central and peripheral systems.


Mechanistic Specificity and Limitations

The drug primarily engages mechanisms that influence lipid-mediated inflammatory responses. Its scope is defined by its target: it does not affect the 5-Lipoxygenase (5-LOX) pathway, meaning inflammatory responses driven by leukotrienes remain unmodulated. Furthermore, the binding to the COX enzymes is reversible, which means its effects on physiological processes maintained by COX-1, such as platelet function, are transient and dependent on circulating drug levels.

Dosage and Administration Information

Official Administration Guidelines for Flamic

Flamic (Diclofenac) is utilized in accordance with established administration protocols. The primary guideline for all systemic forms is to use the lowest effective dose for the shortest duration possible.


Dosing and Administration

The medicine is available for oral (tablets, powder), rectal (suppositories), parenteral (injection), and topical (gel/solution) use, allowing for systemic or localized effects. The maximum total systemic daily dose generally should not exceed 150 mg, encompassing all systemic forms used.

Administration Method Standard Dosing Principles Key Procedural Instruction
Oral (Immediate-Release) 50 mg two or three times daily, or 75 mg twice daily, in divided doses. Tablets should generally be taken with food or water to assist with gastric tolerability.
Oral (Extended-Release) Typically 100 mg once daily. Must be swallowed whole and must not be crushed, chewed, or divided to preserve the slow-release properties.
Parenteral (Injection) 75 mg once or twice daily. The use of the injection is typically limited to two days; treatment should transition to oral or rectal forms thereafter. Intramuscular injection must be administered as a deep intragluteal injection.

Population-Specific Rules

In older adults, the lowest effective dosage must be utilized, and patients are subject to closer monitoring. While no specific dose adjustment is necessary for mild to moderate renal dysfunction, the use of Flamic is generally not recommended in patients with severe renal or hepatic impairment.

Missed Dose

If a dose is missed, it should be taken as soon as it is remembered. However, patients must not take a double dose to compensate for the missed amount.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flamic

Evidence for Managing Pain and Inflammation in Arthritis

Flamic was studied for conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis and inflammatory arthritis, based on Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored outcomes related to physical discomfort, including measuring pain intensity and assessing changes in physical function over defined time intervals. Research highlights changes measured during the study period related to these measurable symptomatic endpoints over short-term evaluation periods (e.g., 4 to 12 weeks).

What remains uncertain is the full picture of outcomes over very long periods. While observational settings evaluating daily-life functioning have been used, randomized evidence specifically tracking sustained functional benefits for multiple years is limited.

Evidence for Acute, Short-Term Pain Relief

The evidence base for acute pain, including outcomes related to physical discomfort (e.g., postoperative, dental, and musculoskeletal aches), was evaluated in short-term, single-dose RCTs. The outcomes measured focused intensely on outcomes describing episodic or acute changes, such as the time needed to reach the reported onset of relief and the patient-reported requirement for rescue pain medication over brief periods. Data show patterns related to symptom intensity or variability measured in the studies.

Comparative evidence is lacking across all available forms (oral, topical, injection) for every specific acute pain type. Data for certain younger age groups, especially children below 12 years old, remains insufficient.

Evidence for Acute Migraine and Menstrual Pain

Flamic was evaluated in research contexts involving conditions presenting with cycles of stability and flare-ups, specifically acute migraine attacks and primary dysmenorrhea (menstrual pain). For acute migraine, studies monitored outcomes describing episodic or acute changes, such as research exploring outcomes related to freedom from pain at the 2-hour time point. Studies exploring primary dysmenorrhea examined patient-reported outcomes describing perceived discomfort, focusing on pain intensity scores.

For menstrual pain, the research is focused solely on the short-term use during a cycle, and long-term menstrual health outcomes are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Flamic (FAQ)

Q: Is Flamic the same as other medicines used for [condition Flamic treats]?

A: Flamic is the brand name for the active ingredient Diclofenac, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

According to official documents, its action is based on non-selective inhibition of the COX enzymes. This mechanism positions it alongside other NSAIDs used to address pain and inflammation.

Q: How long does it typically take for Flamic to start working?

A: The onset of the medicine's effect varies depending on the formulation used. Official pharmacokinetic data indicates that relief from oral tablets may begin after 1 to 4.5 hours.

Injectable forms typically reach their peak effect around 1.5–2 hours after administration, with some studies showing activity starting within 15–30 minutes.

Q: Does Flamic cause weight gain or weight loss?

A: Official labeling lists general 'weight changes' under the Metabolic and Nutritional adverse events section.

More importantly, unexplained weight gain is documented as a serious side effect, as this can be a sign of fluid retention or edema (swelling).

Q: Is it common to feel sleepy or tired when starting Flamic?

A: Side effects reported in the official product information include drowsiness, tiredness, and asthenia (lack of energy).

If these effects occur, the official product information advises caution regarding activities like driving or operating machinery.

Q: How long do the side effects of Flamic usually last?

A: Regulatory health authorities suggest that mild and common side effects, such as dizziness or headache, may lessen as the body adjusts to the medicine.

Conversely, serious side effects are documented to occur at any time during treatment and are typically reported to a healthcare professional.

Q: Is Flamic safe for older adults (seniors)?

A: Flamic is used in older adults, but regulatory documents highlight that this population is at a greater risk for serious side effects, especially gastrointestinal events.

Official guidance emphasizes the need for closer monitoring during treatment, and product information suggests using the lowest effective dose for the shortest duration possible.

Q: Is Flamic known to be habit-forming or addictive?

A: Flamic's active ingredient, Diclofenac, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

This drug class is not generally associated with being habit-forming or having addictive properties.

Q: What are the signs that Flamic is working correctly?

A: The core benefits of Flamic, as documented in regulatory materials, are to mitigate the symptoms of inflammation.

Signs that the medicine is working are generally a reduction in pain perception, the relief of swelling, and a normalization of an elevated body temperature.

Q: Is Flamic safe to use while breastfeeding?

A: Information from expert sources suggests that, while the active ingredient is found in small amounts in breast milk, it is typically used with caution under the guidance of a healthcare professional.

Lower exposure is generally observed with the topical gel formulation.

Q: Are there long-term studies available about Flamic's safety?

A: Regulatory safety information indicates that the risk of serious adverse events, such as heart attack, stroke, and gastrointestinal bleeding, increases with the duration and dosage of Flamic.

Due to this documented risk, official guidelines stress that treatment should be limited to the lowest effective dose for the shortest duration possible.

Q: What is the difference between Flamic and a generic version of the medicine?

A: Flamic is the brand name used for the medicine containing the active ingredient Diclofenac Sodium.

A generic version contains the identical active substance and is regulated to work in the same way, but it is typically marketed under a different, non-proprietary name.

Q: Does Flamic affect birth control pills?

A: Official documents do not typically list a direct interaction between Flamic and hormonal birth control pills.

However, if the medicine causes gastrointestinal side effects like vomiting or severe diarrhea, the absorption and effectiveness of oral contraceptives may be compromised.

Q: Why do official documents list so many possible interactions for Flamic?

A: Flamic is a COX inhibitor, meaning it influences the production of prostaglandins, which are key regulators of body functions like blood pressure and kidney operation.

This mechanism explains why regulatory documents list interactions with many medicines that also affect these systems, such as diuretics or blood pressure medications.

Q: Is Flamic a medicine that needs to be taken long-term?

A: According to regulatory guidelines, Flamic should be taken for the shortest duration possible, using the lowest effective dose.

This protocol is intended to minimize the risk of serious side effects, consistent with regulatory caution against prolonged use.

Q: What does it mean if Flamic is only approved for certain uses?

A: Approved or indicated uses refer to the specific conditions for which the drug has been reviewed by official regulatory authorities (like the FDA or EMA).

The medicine has been officially documented as effective and safe only for these conditions, as described in the product's official labeling.

Q: Is Flamic supposed to be taken at a specific time of day?

A: Official administration instructions define the required dosing frequency, such as once or twice daily, to ensure consistent drug levels in the body.

However, the regulatory guidance does not typically mandate a specific time of day, emphasizing that adherence to the dosing schedule is the most important factor.

Q: How often do people have to go to the doctor while taking Flamic?

A: Official administration guidelines specify that patients with certain pre-existing conditions, particularly older adults and those with organ impairment, require closer monitoring.

The frequency of follow-up appointments is determined by the healthcare professional, based on individual health status and documented risk factors.

Q: Is it normal to have vivid dreams when taking Flamic?

A: The official adverse reaction list for Flamic includes 'dream abnormalities' as a possible effect under the Nervous System category.

If you experience vivid or unusual dreams, this is a recognized potential side effect.

Q: What is the purpose of the 'Warnings' section in the Flamic leaflet?

A: The Warnings section, which may include a Boxed Warning by the FDA, is mandatory regulatory content.

Its purpose is to officially alert both patients and healthcare professionals to the most serious and potentially life-threatening risks associated with the medicine, such as cardiovascular events and serious gastrointestinal bleeding.

Q: Do I need to change my diet while taking Flamic?

A: Regulatory documents state that alcohol use should be avoided due to a documented increased risk of serious gastrointestinal problems.

Also, some oral forms must be taken on an empty stomach, while others should be taken with food. No other specific general dietary change is mandated in the official information.

Q: Are there different brand names for the medicine Flamic?

A: Flamic is a brand name containing the active ingredient Diclofenac.

The active ingredient itself is sold under many different brand names and generic versions worldwide, depending on the country and manufacturer.

Q: Does Flamic affect laboratory blood test results?

A: Official labeling reports that Flamic can cause changes in blood cell counts (such as low red or white blood cells) and affect certain lab test markers.

This includes markers related to organ function, specifically the liver and kidneys.

Q: What does the term 'contraindication' mean for Flamic?

A: A contraindication is a clear and absolute prohibition defined in regulatory materials.

It means that the medicine must not be used because the documented health risks, such as a history of severe allergic reactions or established severe cardiovascular disease, outweigh any potential benefit in that situation.

Q: Why is it important to know how Flamic works?

A: Official documents explain that Flamic works by reducing inflammatory prostaglandins.

Understanding this mechanism is important because it explains both the intended benefits (reducing pain and swelling) and why the drug carries documented risks to systems also regulated by these chemicals, such as the GI tract and the kidneys.

Q: Does Flamic have a 'Black Box Warning'?

A: Yes, the active ingredient in Flamic (Diclofenac) is subject to the FDA's Boxed Warning, sometimes informally referred to as a Black Box Warning.

This serious alert concerns the risk of cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding).

Q: Can Flamic cause problems with driving or operating machinery?

A: Official product information warns that if you experience certain side effects, such as dizziness, drowsiness, blurred vision, or vertigo, your ability to drive or operate machinery may be affected.

The official warning indicates that the activity should be avoided if symptoms are present.

Q: Is Flamic generally considered well-tolerated?

A: Official safety summaries categorize common side effects, which primarily affect the gastrointestinal system (such as nausea and indigestion) and the nervous system (such as headache and dizziness).

However, patients are monitored closely for rare but serious adverse events, including GI bleeding and cardiovascular issues.

Q: Does taking Flamic make you more sensitive to the sun?

A: Yes, photosensitivity (increased sensitivity to sunlight) has been reported as an adverse reaction in the official product information.

Because of this, the product information contains a caution regarding exposure to bright sun and recommends the use of appropriate sun protection.

How should Flamic be stored and disposed of?

Storage and Disposal Requirements

Flamic (Diclofenac) must be stored according to regulatory requirements specific to its form to maintain stability. Oral tablets are generally required to be stored at room temperature, often not exceeding 25 C or 30 C. The medicine must be kept in its original pack and in a tightly closed container to protect it from moisture and light. It is a mandatory requirement to keep this medicine out of the sight and reach of children.

After use, the product must not be thrown away in household waste or wastewater. Unused or expired Flamic must be disposed of in accordance with local regulations, and users should consult a pharmacist for guidance on take-back programs or safe disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flamic found in:

A-Z Index: